Want to see KR:001630 full AI Analyst Report?
Top Page
Chong Kun Dang Holdings Co., Ltd.
(001630)
Select Model
Select Model
Rating:59Neutral
Price Target:
₩37,045.00
Action:N/A
Date:10/28/26
The score is held back primarily by weak cash conversion and mixed operating profitability, alongside a clearly bearish technical setup (below key moving averages with negative momentum). These risks are partially offset by very attractive valuation metrics (low P/E and solid dividend yield) and improved net profitability in the latest TTM period.
Positive Factors
Revenue rebound
The sharp TTM revenue rebound indicates renewed demand and improved commercial performance across the healthcare portfolio. If sustained, stronger top-line scale can support broader cost absorption, reinforce subsidiary operations, and provide a foundation for more durable earnings growth over the next several quarters.
Negative Factors
Weak cash conversion
Weak conversion of accounting profit into free cash flow reduces the funds available for research, acquisitions, debt reduction, and shareholder distributions. The sharp FCF decline also raises concerns about earnings quality and makes future investment capacity more dependent on operating improvement or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The sharp TTM revenue rebound indicates renewed demand and improved commercial performance across the healthcare portfolio. If sustained, stronger top-line scale can support broader cost absorption, reinforce subsidiary operations, and provide a foundation for more durable earnings growth over the next several quarters.
Read all positive factors
Chong Kun Dang Holdings Co., Ltd. (001630) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩169.24B
Dividend Yield3.94%
Average Volume (3M)2.19K
Price to Earnings (P/E)2.6
Beta (1Y)0.18
Revenue Growth1.43%
EPS Growth106.56%
CountryKR
Employees38
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)13624.32
Shares Outstanding5,009,861
10 Day Avg. Volume2,851
30 Day Avg. Volume2,191
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)0.36
Price to Sales (P/S)0.24
P/FCF Ratio11.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5,712
Revenue Forecast (FY)₩1.11T
Chong Kun Dang Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
Based in Seoul, South Korea, Chong Kun Dang Holdings Corp. has manufactured and supplied pharmaceutical goods since its inception in 1941, reaching both South Korean and global markets....
Chong Kun Dang Holdings Co., Ltd. Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
60
Neutral
Cash Flow
49
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 961.64B | 959.01B | 957.75B | 879.78B | 908.96B | 925.98B |
| Gross Profit | 399.80B | 415.90B | 444.58B | 383.86B | 399.19B | 441.41B |
| EBITDA | 5.75B | 102.31B | 104.32B | 56.07B | 13.61B | 72.54B |
| Net Income | 53.67B | 40.43B | 33.60B | 47.01B | 1.07B | 15.99B |
Balance Sheet | ||||||
| Total Assets | 1.75T | 1.63T | 1.50T | 1.46T | 1.38T | 1.37T |
| Cash, Cash Equivalents and Short-Term Investments | 154.23B | 115.56B | 61.12B | 81.16B | 82.81B | 144.92B |
| Total Debt | 602.87B | 540.81B | 479.65B | 468.03B | 429.34B | 345.32B |
| Total Liabilities | 814.73B | 715.73B | 646.03B | 632.52B | 577.83B | 527.67B |
| Stockholders Equity | 656.17B | 637.02B | 587.50B | 562.95B | 528.87B | 540.98B |
Cash Flow | ||||||
| Free Cash Flow | 10.21B | 20.20B | 67.51M | 5.07B | -111.77B | -62.68B |
| Operating Cash Flow | 99.20B | 76.04B | 24.48B | 37.15B | -46.50B | 40.46B |
| Investing Cash Flow | -160.72B | -72.86B | -37.53B | -23.99B | -64.69B | -108.05B |
| Financing Cash Flow | 80.39B | 47.87B | -3.82B | -4.13B | 67.04B | 108.99B |
Chong Kun Dang Holdings Co., Ltd. Technical Analysis
Negative
―
Price Trends
37932.00
Negative
38769.50
Negative
43184.77
Negative
Market Momentum
-724.17
Positive
22.07
Positive
20.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:001630, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 36575.00, equal to the 50-day MA of 37932.00, and equal to the 200-day MA of 43184.77, indicating a bearish trend. The MACD of -724.17 indicates Positive momentum. The RSI at 22.07 is Positive, neither overbought nor oversold. The STOCH value of 20.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:001630.
Chong Kun Dang Holdings Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩560.29B | 5.53 | ― | 2.80% | 10.50% | 96.29% | |
60 Neutral | ₩404.42B | 8.96 | ― | 1.56% | -0.65% | ― | |
59 Neutral | ₩169.24B | 2.61 | ― | 3.94% | 1.43% | 106.56% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩299.64B | 12.56 | ― | 1.57% | 5.50% | -26.11% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
46 Neutral | ₩332.73B | -56.26 | ― | 2.01% | 15.38% | ― |
* General Sector Average
KR:001630
Chong Kun Dang Holdings Co., Ltd.
35,550.00
-9,206.72
-20.57%
KR:001060
JW Pharmaceutical Corporation
23,200.00
191.16
0.83%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
95.20
2.60%
KR:009290
Kwang Dong Pharmaceutical Co., Ltd.
6,370.00
567.55
9.78%
KR:170900
Dong-A ST Co., Ltd.
34,900.00
-8,968.36
-20.44%
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,790.00
-10,206.94
-44.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.